Candel Therapeutics announced EMA Orphan Designation for CAN-2409, a pancreatic cancer treatment, highlighting significant unmet medical needs.
Quiver AI Summary
Candel Therapeutics, Inc. has announced that the European Medicines Agency (EMA) has granted Orphan Designation for its investigational treatment CAN-2409 for pancreatic cancer, complementing its existing FDA designations in the U.S. This recognition highlights the significant unmet medical need for this challenging disease. CAN-2409 is an engineered adenovirus designed to induce an immune response against tumors by delivering a gene that activates a prodrug to cause cell death and release tumor antigens. Positive results from a Phase 2a trial showed improved survival rates for patients receiving CAN-2409 compared to standard care. The Orphan Designation provides Candel with benefits such as reduced fees and potential market exclusivity, further emphasizing the promise of its innovative immunotherapy approach to benefit patients with limited treatment options.
Potential Positives
- European Medicines Agency (EMA) granted Orphan Designation for CAN-2409 for the treatment of pancreatic cancer, complementing its existing FDA Orphan Drug and Fast Track Designations.
- The press release highlights positive overall survival data from a phase 2a clinical trial, with an estimated median overall survival of 31.4 months for patients treated with CAN-2409 compared to 12.5 months in the control group.
- CAN-2409 demonstrates transformative potential in modifying the tumor microenvironment and inducing a systemic immune response, which could address significant unmet medical needs in cancer treatment.
- The EMA Orphan Designation allows Candel Therapeutics potential benefits such as reduced regulatory fees and up to 10 years of market exclusivity in the European Union if approved.
Potential Negatives
- Despite the positive regulatory designations for CAN-2409, the press release highlights that pancreatic cancer remains challenging to treat, implying a significant ongoing unmet medical need in the market.
- The reliance on interim clinical trial data raises concerns about the robustness and reliability of the claims regarding CAN-2409’s efficacy and survival benefits, as future data may vary from reported results.
- The mention of risks and uncertainties in the forward-looking statements section underscores potential challenges in the company’s ability to deliver on its promises, which could impact investor confidence.
FAQ
What is CAN-2409's significance in treating pancreatic cancer?
CAN-2409 has received Orphan Designation from the EMA, recognizing its potential to address significant unmet medical needs in pancreatic cancer treatment.
What regulatory designations has CAN-2409 received?
CAN-2409 has FDA Orphan Drug Designation, Fast Track Designation, and EMA Orphan Designation for pancreatic cancer and additional designations for other indications.
How does CAN-2409 work?
CAN-2409 is designed to deliver the HSV-tk gene to tumor cells, leading to immunogenic cell death and an immune response against various tumors.
What are the survival benefits observed in CAN-2409 trials?
In trials, CAN-2409 demonstrated a median overall survival of 31.4 months in patients with borderline resectable pancreatic cancer, compared to 12.5 months with standard care.
Who is Candel Therapeutics?
Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative multimodal biological immunotherapies for cancer treatment.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CADL Insider Trading Activity
$CADL insiders have traded $CADL stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $CADL stock by insiders over the last 6 months:
- WILLIAM GARRETT NICHOLS (Chief Medical Officer) sold 45,316 shares for an estimated $396,995
- FRANCESCA BARONE (Chief Scientific Officer) sold 32,146 shares for an estimated $281,672
- SESHU TYAGARAJAN (Chief Technology Officer) sold 31,278 shares for an estimated $275,947
- PAUL PETER TAK (Chief Executive Officer) has made 0 purchases and 2 sales selling 26,172 shares for an estimated $229,624.
- CHARLES SCHOCH (See Remarks) sold 5,000 shares for an estimated $44,169
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CADL Hedge Fund Activity
We have seen 57 institutional investors add shares of $CADL stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 3,161,717 shares (+80.6%) to their portfolio in Q1 2025, for an estimated $17,863,701
- BRAIDWELL LP removed 1,600,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $9,040,000
- BLACKROCK, INC. added 579,823 shares (+49.0%) to their portfolio in Q1 2025, for an estimated $3,275,999
- BAKER BROS. ADVISORS LP removed 544,794 shares (-18.3%) from their portfolio in Q1 2025, for an estimated $3,078,086
- VANGUARD GROUP INC added 396,954 shares (+29.6%) to their portfolio in Q1 2025, for an estimated $2,242,790
- CITADEL ADVISORS LLC removed 281,513 shares (-96.7%) from their portfolio in Q1 2025, for an estimated $1,590,548
- MARSHALL WACE, LLP added 234,597 shares (+inf%) to their portfolio in Q1 2025, for an estimated $1,325,473
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CADL Analyst Ratings
Wall Street analysts have issued reports on $CADL in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/30/2025
- Canaccord Genuity issued a "Buy" rating on 02/26/2025
- Citigroup issued a "Buy" rating on 02/20/2025
- B of A Securities issued a "Buy" rating on 02/07/2025
To track analyst ratings and price targets for $CADL, check out Quiver Quantitative's $CADL forecast page.
$CADL Price Targets
Multiple analysts have issued price targets for $CADL recently. We have seen 5 analysts offer price targets for $CADL in the last 6 months, with a median target of $23.0.
Here are some recent targets:
- Andrew Fein from HC Wainwright & Co. set a target price of $23.0 on 06/30/2025
- John Newman from Canaccord Genuity set a target price of $25.0 on 02/26/2025
- Yigal Nochomovitz from Citigroup set a target price of $25.0 on 02/20/2025
- Alec Stranahan from B of A Securities set a target price of $15.0 on 02/07/2025
Full Release
NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. This designation complements CAN-2409’s existing U.S. Food and Drug Administration (FDA) Orphan Drug Designation and FDA Fast Track Designation for the treatment of pancreatic ductal adenocarcinoma (PDAC) awarded to CAN-2409 in April 2024 and December 2023, respectively, and underscores the significant unmet medical need in this disease beyond the U.S.
CAN-2409 is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to tumor cells. When administered with a prodrug (valacyclovir or acyclovir), the HSV-tk enzyme converts the prodrug into DNA-incorporating nucleotide analogs, causing immunogenic cell death and the release of tumor (neo)antigens within the tumor microenvironment (TME). This mechanism has the potential to induce an individualized, systemic immune response against multiple therapy-resistant solid tumors, including prostate cancer, non-small cell lung cancer (NSCLC), and PDAC.
The Company previously reported positive overall survival (OS) data from its randomized controlled phase 2a clinical trial of CAN-2409 plus valacyclovir in borderline resectable PDAC, demonstrating remarkable survival benefits with estimated median OS of 31.4 months in the CAN-2409 plus standard of care arm versus 12.5 months in the standard of care control arm, supported by immunological biomarker data. Notably, three of seven patients treated with CAN-2409 were still alive at the time of data cut-off (February 20, 2025) with survival of 66.0, 63.6 and 35.8 months after enrollment, respectively, suggesting a long tail of survival.
“Pancreatic cancer remains one of the most challenging malignancies to treat, particularly in patients whose disease is unresectable,” said Garrett Nichols, MD, MS, Chief Medical Officer at Candel. “We observed that CAN-2409 profoundly remodels the tumor microenvironment, transforming it from ‘cold’ (non-inflamed and immunosuppressive) to ‘hot’ (inflamed with active immune infiltration) and extends survival.”
The EMA grants Orphan Designation to drugs and biologics intended for the treatment, diagnosis or prevention of rare, life-threatening or chronically debilitating diseases or conditions that affect fewer than five in 10,000 people in the European Union. Orphan Designation allows pharmaceutical companies certain benefits, including reduced regulatory fees, clinical protocol assistance, research grants and up to 10 years of market exclusivity in the European Union, if approved.
“Receiving EMA Orphan Designation for CAN-2409 represents a significant regulatory milestone for CAN-2409 in this disease,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “This designation, alongside our existing FDA Orphan Drug and Fast Track Designations for CAN-2409 in PDAC, underscores the promise of our novel multimodal immunotherapy approach. The notable benefits we’ve observed with CAN-2409, including evidence of a long tail of survival, highlight the transformative potential of this immunotherapy. As we advance our regulatory strategy across global markets, we remain committed to bringing CAN-2409 to patients who face limited therapeutic options. We look forward to continuing our development efforts and working with regulatory authorities across the world to make this innovative therapy available to patients in need.”
CAN-2409 has received regulatory designations recognizing its potential across multiple solid tumor indications. In addition to the EMA Orphan Designation announced today and the FDA Orphan Drug Designation and FDA Fast Track Designation for PDAC mentioned above, CAN-2409 has also received FDA Fast Track Designation for NSCLC and localized prostate cancer, as well as FDA Regenerative Medicine Advanced Therapy designation (RMAT) for intermediate-to-high risk, localized prostate cancer.
About CAN-2409
CAN-2409 (aglatimagene besadenovec), Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid protein promotes inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. CAN-2409 has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors have previously been shown in several preclinical and clinical settings. More than 1,000 patients have been dosed with CAN-2409 with a favorable tolerability profile to date, supporting the potential for combination with standard of care, when indicated.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform.
The Company recently completed successful phase 2a clinical trials of CAN-2409 in NSCLC and PDAC, and a pivotal, placebo-controlled phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the FDA. Additionally, the FDA very recently granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease.
CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult to treat, solid tumors; and expectations regarding the potential benefits conferred by Orphan Designation. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact:
Theodore Jenkins
VP, Investor Relations and Business Development
Candel Therapeutics, Inc.
[email protected]
Media Contact:
Ben Shannon
ICR Healthcare
[email protected]